Outcomes of cost-effectiveness analysis
| Combinations | Cost (C) (yuan) | Effectiveness (E) % | C/E | ΔC/ΔE |
| CEA+CA125 | 87 | 75.85 | 1.15 | 0.00 |
| CEA+CA211 | 132 | 77.03 | 1.71 | 20.68 |
| CA50+CA211 | 155 | 75.20 | 2.06 | 194.20 |
| CEA+CA50+CA125 | 142 | 84.08 | 1.69 | 5.96 |
| CEA+CA50+CA211 | 187 | 88.27 | 2.12 | 7.45 |
| CEA+CA125+CA211 | 187 | 84.86 | 2.20 | 9.99 |
| CA50+CA125+CA211 | 210 | 83.65 | 2.51 | 13.97 |
| CEA+CA50+CA125+CA211 | 242 | 92.27 | 2.62 | 8.90 |
| CEA+NSE+SCC | 196 | 76.82 | 2.55 | 55.46 |
| CEA+NSE+CA211 | 196 | 84.08 | 2.33 | 11.81 |
| CEA+SCC+CA211 | 232 | 83.75 | 2.77 | 16.29 |
| NSE+SCC+CA211 | 264 | 76.19 | 3.46 | 131.80 |
| CEA+NSE+SCC+CA211 | 296 | 88.74 | 3.34 | 15.05 |
CA50, cancer antigen-50; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase; SCC, squamous cell carcinoma antigen.